Empagliflozin is a SGLT-2 inhibitor and it has shown to significantly reduce the progression of kidney disease and heart failure.

With the expiration of Boehringer Ingelheim’s patent on Empagliflozin, several Indian pharmaceutical companies are set to ...

Domestic drug companies in India are preparing to launch affordable generics of the diabetes drug Empagliflozin after the ...

Indian Pharmaceuticals Market has delivered marginally lower revenue at 7.5% year on year in February 2025, compared to 8.7% ...

Lupin announced that it has launched Rivaroxaban tablets USP, 2.5 mg, in the US market following final approval from the US Food and Drug Administration (USFDA) for its abbreviated new drug ...

Lupin's shares increased by 21.51% over the past year. However, year-to-date (YTD), the stock has decreased by 14.21%. Over ...

For Yashwant Mahadik, President, Global Human Resources at Lupin, a pharmaceutical company, photography is more than a hobby. It is a way of life. What began as ...

Mumbai: Global pharma major Lupin Limited has announced that it has launched Rivaroxaban Tablets USP, 2.5 mg, following the ...

This follows the final approval from the US FDA for its abbreviated new drug application (ANDA). Shares of Lupin Ltd ended at ...

Indian Pharmaceutical Alliance Pushes for Zero Import Duty on US Drugs to Strengthen Local Industry - The Indian Pharmaceutical Alliance (IPA), representing major drug manufacturers like Cipla , Dr.

Lupin has launched Rivaroxaban Tablets USP, 2.5 mg, following the final approval of its Abbreviated New Drug Application from the U.S. FDA.